FACULTY COMMENTS

DR RAVDIN: We have all seen disappointing circumstances in which disease recurs after 10 years. The data indicate that recurrence risk is stable during the first five years, with a substantial risk in years five to 10.

Between years five and 10, patients with node-positive disease have approximately a 20 percent risk of recurrence, while those with node-negative disease have a 10 percent risk. This is true for patients with hormone receptor-positive tumors, but it’s not true for those with hormone receptor-negative tumors, who experience most of their recurrences within the first five years.

DR DIXON: MA17 was a seminal study that reeducated us that among patients with hormone receptor-positive breast cancer, more events occur from years five to 15 than in the first five years.

I believe that everyone is more aware now that the risk of recurrence is almost lifelong. The rate of contralateral or second breast primaries in treated patients continues at the same rate almost forever.

Table of Contents

Top of Page

Home | Search

Editor's Note
State of the art 2008
Neil Love, MD

Slides and Faculty Comments

Sentinel Lymph Node Biospy (LSNB) Relative to Neoadjuvant Systemic Therapy

Neoadjuvant Systemic Therapy

Sentinel Node Biopsy Injection Site

Partial Breast Irradiation (PBI)

Genomic Assays: Prediction of Benefit from Chemotherapy

Hormone Receptor-Positive Breast Cancer

Assessment of Her2 Status

- Select Publications

A CME Audio Series and Activity

Faculty Disclosures

Editor's Office